HISTORY OF OPIOIDS AND ADDICTION AND NON-OPIOID PAIN RELIEF



FRANK LOVECCHIO, DO, MPH, FACEP, ABMT

RESEARCH DIRECTOR, COLLEGE OF HEALTH SOLUTIONS

VALLEYWISE, EMERGENCY MEDICINE, MEDICAL TOXICOLOGY, ADDICTION

PROFESSOR, UNIVERSITY OF AZ COLLEGE OF MEDICINE, PHARMACY,

MEDICINE AND EMERGENCY MEDICINE

PROFESSOR, EMERGENCY MEDICINE, CREIGHTON SCHOOL OF MEDICINE PHOENIX, AZ

CASES

A 40-year-old woman with a severe headache and non focal examination.

A 30-year-old man with sudden onset left flank pain who looks uncomfortable and otherwise normal examination.

NON-OPIOID PAIN MANAGEMENT "OPIOID FREE ED AND UC"

Renal colic acetaminophen, indomethacin, ketorolac, lidocaine, rectal indomethacin Back pain
acetaminophen,
diazepam, ibuprofen,
lidocaine patch,
methocarbamol, triggerpoint myofascial injections

Headache diphenhydramine, ketorolac, metoclopramide, prochlorperazine, sumatriptan, CGRP antagonist

Musculoskeletal pain acetaminophen, ibuprofen, lidocaine patch, naproxen, nitrous oxide, regional nerve blocks

Neuropathic pain clonidine, gabapentin, ibuprofen, nortriptyline, pregabalin

Burns acetaminophen, bupivacaine, ibuprofen, naproxen, nitrous oxide

Sickle cell crisis hydroxyurea, ibuprofen, ketamine, nitrous oxide Chronic pain gabapentin, ibuprofen, lidocaine patch, prednisone, trigger-point injections

Pediatric pain acetaminophen, ibuprofen, ketamine, nitrous oxide

KETAMINE




Dose	Effect	
0.1 - 0.3 mg/kg	Analgesia	
0.2 – 0.5 mg/kg	Recreational	
0.4 – 0.8 mg/kg	Partially dissociated	
1-2 mg/kg	Fully dissociated	

JAMA

JAMA Insights

Peripheral Nerve Blocks for Hip Fractures



HISTORICAL OPIUM

First used Medicinally in the Stone Age


Sumerian, Assyrian, Egyptian, Indian, Minoan, Greek, Roman, Persian, & Arab Empires all report medicinal use.

Fifteenth Century China first reported recreational use

Opium Wars in 1839 & 1858

International Opium Commission of 1914, followed by the International Narcotics Control Board

DEA



HISTORICAL OPIATES

1804 Friedrich Serturner isolated Morphine

Morphine first marketed by Heinrich Merck

Codeine isolated in 1832

Heroin synthesized in 1874 by the Bayer Pharmaceutical Company











OPIATE ABUSE












Factors Contributing to Vulnerability to Develop a Specific Addiction





TREATMENT OPTIONS


- Best treatment option is <u>PREVENTION!</u>
- Counseling & Behavioral Therapies
 - Individual and group counseling
 - Inpatient and residential treatment
 - Intensive outpatient treatment
 - Case or care management
 - Recovery support services
 - 12-step fellowship
 - Peer supports

- Medication Assisted Treatment
 - Buprenorphine
 - Methadone
 - Naltrexone





Acupuncture



Radiofrequency Ablation



Yoga





Spinal Cord Stimulation



Nerve Blocks




Exercise



Physical Therapy



Transcutaneous Electrical Stimulation



Non-Opioid Medications



Therapeutic Massage

TYPES OF PAIN

Nociceptive

- Tissue damage
- Arthritis, trauma

Mixed

- Neuronal dysfunction
- Fibromyalgia

Neuropathic

- Peripheral or central nerve damage
- Neuropathy, postherpetic neuralgia

TREATMENT MODALITIES

Pharmacological

Physical

Behavioral

Interventiona

Neuropathic Pain

- 1. PO lbuprofen-400-800 mg
- 2. PO Gabapentin-100-300 mg
- 3. PO Prednisone-25-50 mg
- 4. PO Clonidine 0.1-0.2 mg
- 5. IV Ketamine-0.3 mg/kg over 10 min, + IV drip at 0.15 mg/kg /hr
- 6. IV Lidocaine -1.5.-2.5 mg/kg /hr drip x2-4 h (2% cardiac Lidocaine)
- 7. IV Dexemedetomidine-0.2-0.3 mcg/kg/hr drip
- 8. IV Clonidine-0.3-2 mcg/kg/hr drip

Post-Operative Pain

- 1. IV Acetaminophen-1g over 10-15 min
- 2. IV Ketamine-0.3 mg/kg over 10 min, + IV drip at 0.15 mg/kg /hr
- 3. IV Dexemedetomidine-0.2-0.7 mcg/kg/hr drip

Dental Pain

- 1. Dental Blocks
- 2. PO Ibuprofen -400-800 mg
- 3. PO Acetaminophen-500-1000mg

Burns

- 1. PO lbuprofen-400-800 mg
- 2. PO Acetaminophen-500-1000mg
- 3. PO Naproxen-375 mg
- 4. IV Acetaminophen-1g over 15 min
- 5. IV Ketamine-0.3 mg/kg over 10 min, + IV drip at 0.15 mg/kg /hr
- 6. IV Lidocaine -1.5.-2.5 mg/kg /hr drip x2-4 h (2% cardiac Lidocaine)
- 7. IV Dexemedetomidine-0.2-0.7 mcg/kg/hr drip
- 8. IV Clonidine-0.3-2 mcg/kg/hr drip

Sickle Cell Painful Crisis

- 1. PO lbuprofen-800mg
- 2. PO Hydroxyurea-100mg
- 3. IN Ketamine 1mg/kg (no more than 1ml per nostril)
- 4. IV Ketamine-0.3 mg/kg over 10 min, + IV drip at 0.15 mg/kg /hr
- 5. IV Lidocaine -1.5.-2.5 mg/kg /hr drip x2-4 h (2% Cardiac Lidocaine)
- 6. IV Dexemedetomidine-0.2-0.3 mcg/kg/hr drip


Alternatives to Opiates (ALTO®)

www.emra.org

Table 1. Non-Opioid Suggestions for Pain Management in Select Conditions

Condition	Analgesia	
Acute Headache	Ibuprofen/Ketorolac, Acetaminophen, Reglan, Trigger point injection, Magnesium, Valproic Acid, Dexamethasone, Haldol	
Renal Colic	Ketorolac, Acetaminophen, Cardiac lidocaine	
Musculoskeletal Pain (sprains, strains or opiate naive low back pain)	Ibuprofen/Ketorolac, Acetaminophen, Cyclobenzaprine, Lidocaine patch, Gabapentin, Trigger point injection	
Acute on Chronic Radicular Low Back Pain (opiate tolerant)	Ibuprofen/Ketorolac, Acetaminophen, Cyclobenzaprine, Lidocaine patch, Gabapentin, Trigger point injection, Dexamethasone, Ketamine	
Extremity Fracture or Joint Dislocation	Acetaminophen, Ketamine Intranasal, Nitrous Oxide, Ultrasound guided regional anesthesia	

PHARMACOLOGICAL OPTIONS



TOPICALS

Lidocaine: ointment, cream, gel, patch

Potentially effective for neuropathic pain

5% patch: 3 patches for up to 12 hours during a 24 hour period

4% patch is available OTC

Doxepin

Treatment of pruritis, minimal effect on pain

Capsaicin

Repeated application is thought to deplete substance P

Adverse effects: burning, stinging, erythema

Avoid other forms of heat (sun, shower) and wash hands thoroughly

NSAID

Pros

Analgesic, anti-inflammatory, antipyretic

Benefit in the treatment of different types of pain


Cons

Nephrotoxic, hepatotoxic


Increase in blood pressure

Potential to cause GI ulceration/bleeding and CV events

NSAID Side Effects:



Low dose aspirin irreversibly inhibits platelet COX-1



NSAID: RISK

Risk factors for GI event

Male gender

Age ≥60

Hx of peptic ulcer

Dyspepsia

CVD

Use of antiplatelets, anticoagulants, steroids, high-dose NSAID

Risk factors for CV event

Hx of CV event

DM

HTN

HLD

Obesity

NSAID: GI RISK

Low

- Celecoxib, lowdose ibuprofen
- Meloxicam, nabumetone, etodolac

Moderate

 Naproxen, highdose ibuprofen

High

 Ketorolac, piroxicam

1. Clinical Resource, Managing NSAID Risks, Pharmacist's Letter/Prescriber's Letter. July 2018.

NSAID: MANAGING GI RISK

Misoprostol

- Recommended dose: 200 mg four times daily
- Reduces risk of gastroduodenal complications by 40%

PPI

Protective against NSAID-induced ulcer bleeding

H2RA

- Standard dose: reduce risk of NSAID-associated duodenal ulcers
- High-dose: reduce risk of duodenal and gastric ulcer

NSAID: MANAGING RISK


Patient Factors	Low GI Risk	Moderate GI Risk	High GI Risk
Low CV Risk	Celecoxib or other low-GI risk NSAID	 Celecoxib alone NSAID + PPI, misoprostol, double- dose H2RA 	 Avoid NSAID if possible Celecoxib + PPI or misoprostol
High CV Risk	 Naproxen or low-dose celecoxib If on aspirin, naproxen + gastroprotection 	 Naproxen + PPI, misoprostol, double- dose H2RA Low-dose celecoxib 	Avoid NSAID

CANNABIS AND CANNABINOIDS

Use for chronic pain is controversial

Systematic reviews and meta analyses of trials looking at multiple populations and formulations have found some evidence for efficacy

Small evidence for neuropathic pain, but insufficient evidence for other types of chronic pain



^{1.} Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015; 313:2456.

^{2.} Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA 2015; 313:2474.

^{3.} Andreae MH, Carter GM, Shaparin N, et al. Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J Pain 2015; 16:1221.

http://www.health.state.mn.us/topics/cannabis/intractable/medicalcannabisreport.pdf.

^{5.} Nugent SM, Morasco BJ, O'Neil ME, et al. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review. Ann Intern Med 2017; 167:319.

CANNABIS AND CANNABINOIDS

Cannabidiol (CBD)

Anecdotally effective for some patients

Oil, cream, lotion, gel, ointments, edibles, etc.

ADE: dizziness, dry mouth, fatigue, euphoria, disorientation, hallucination

NONPHARMACOLOGIC AL TREATMENTS

CBT

Acupuncture

Physical therapy

Occupational therapy

Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49.

^{2.} Nielsen S, Lintzeris N, Bruno R, et al. Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization. Pain Med 2015; 16:356.

TAKE HOME POINTS

There are many non-opioid treatment options for chronic pain

Recommend a multimodal and interdisciplinary care, including nonpharmacological therapies

Use an individualized approach taking into account patient-specific factors to guide treatment selection